PRTN3 and rheumatoid arthritis: The frequencies of ACPAs reactive with single autoantigen-derived peptides are in most patient cohorts lower than the frequency of anti-CCP2 reactive antibodies, whereas the number of RA patients who are positive for any of these ACPA fine specificities is similar to the number of anti-CCP2-positive patients (typically around 60% to 70%)[21].